NASDAQ:NXTC
NextCure, Inc.
NextCure, Inc. reported net income of −$55.8M in fiscal 2025. The diluted share count rose 22.0%.Summary generated from NextCure, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−111.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+22.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −71 | −76 | −68 | −60 | −58 |
| Net income | −69 | −75 | −63 | −56 | −56 |
| Free cash flow | −60 | −56 | −54 | −41 | n/a |
Recent filings
- 8-KOther events
Sep 25, 2026 - 8-KEntry into a material agreement
Sep 3, 2026 - 4Insider transaction report
Aug 12, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 4Insider transaction report
Aug 3, 2026 - 8-KEntry into a material agreement
Jul 14, 2026 - 8-KDirector or officer change
Jun 25, 2026